Business
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
CARLSBAD, Calif., August 12, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today reported its second quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
About this update from Lineage Cell Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1740,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/5ef208ae660b6b408d4ccce303882d2a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D3QkSpIlsKKeOZuudy0ylg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5ef208ae660b6b408d4ccce303882d2a","width":960,"height":199},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/G2NJmJwtr1ppvRbbB1JzvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00OTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5ef208ae660b6b408d4ccce303882d2a","width":1200,"height":248}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025","length":116,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Successfully Reduced-to-Practice Critical Aspect of Commercial-Scale, Cell-Based, GMP Production Processes","length":106,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"First Chronic Patient Treated in New Clinical Study of OPC1 in Patients with Subacute and Chronic Spinal Cord Injury ","length":116,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Hosted the 3rd Annual SCI Investor Symposium","length":44,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":382,"olType":false},{"type":"text","content":"CARLSBAD, Calif., August 12, 2025--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today reported its second quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.","length":471,"tagName":"p"},{"type":"text","content":""Following the recent positive 36-month clinical data update with the OpRegen RPE cell therapy program, which is licensed by Genentech and Roche, we continue to remain confident in its potential to address a significant medical need, especially because long term clinical outcomes following a single adminis...